5.2 CMV: Risk Stratification, Letermovir Prophylaxis & DNAemia Treatment

Viral Infections: CMV Reactivation, Letermovir, EBV/PTLD, Adenovirus & HHV-6 Encephalitis

Core Clinical Principle: Following allogeneic transplantation, profound suppression of donor-derived T-cell immunity permits latent double-stranded DNA herpesviruses and polyomaviruses to reactivate. Cytomegalovirus (CMV), Epstein-Barr Virus (EBV), and Human Herpesvirus-6 (HHV-6) can progress rapidly from asymptomatic viremia to catastrophic, life-threatening organ disease. Modern clinical management relies on risk-stratified primary prophylaxis (letermovir), routine quantitative molecular surveillance (real-time PCR), and preemptive antiviral intervention prior to irreversible tissue injury.

1. Cytomegalovirus (CMV): Pathophysiology, Risk Stratification & Organ Disease

CMV (Human Betaherpesvirus 5) establishes lifelong latency within myeloid progenitor cells and endothelial tissues following primary infection. In healthy individuals, robust CD4+ and CD8+ memory T cells keep viral replication suppressed. Post-transplant T-cell depletion, graft-versus-host disease (GVHD), and immunosuppressive medications (corticosteroids, calcineurin inhibitors) disable this control.

Pre-Transplant Serostatus Risk Stratification

Pre-transplant IgG serological testing of both Donor (D) and Recipient (R) defines the baseline risk category:

CMV End-Organ Disease Presentations

1. CMV Pneumonitis:
   • Presentation: Fever, nonproductive cough, dyspnea and hypoxemia with interstitial or ground-glass imaging can occur, but these findings overlap with other infections and noninfectious lung injury.
   • Diagnostics: Bronchoscopy/BAL testing and, when feasible, cytology or tissue are interpreted with plasma viral load and clinical context. BAL PCR alone can reflect pulmonary shedding and is not automatically definitive disease.
2. CMV Gastrointestinal Disease (Enteritis / Colitis / Esophagitis):
   • Clinical Signs: Intractable nausea, vomiting, retrosternal pain (esophagitis), severe watery or bloody diarrhea, abdominal cramping, and mucosal ulcerations.
   • Diagnostic challenge: Distinguish it from acute GI GVHD, medication injury and other infection. Endoscopy with tissue histology/immunohistochemistry is often needed; blood DNAemia alone does not establish GI disease.
3. CMV Retinitis:
   • Presentation: Painless visual loss, floaters, flashing lights (photopsia), and scotomas. Fundoscopy reveals characteristic "pizza-pie" or "cottage cheese and ketchup" appearance (perivascular retinal hemorrhages and dense white retinal infiltrates).
4. Cytopenias and marrow/graft dysfunction:
   • CMV infection and myelosuppressive antiviral therapy can accompany or worsen cytopenias. Evaluate marrow, drugs, other infections, relapse and graft function rather than attributing unexplained counts to CMV alone.

2. CMV Prevention: Letermovir and Surveillance

Letermovir inhibits the CMV terminase complex and is used for prophylaxis—not treatment of established CMV disease—in indicated CMV-seropositive allogeneic HCT recipients. Start within the labeled post-HCT window and continue through day +100; continuation through day +200 is labeled for patients at risk for late CMV infection/disease. Follow age, weight, route, kidney/liver and product-specific instructions.

With cyclosporine, the adult letermovir dose is reduced from 480 mg to 240 mg daily. Letermovir can also increase tacrolimus exposure, so review interactions and monitor concentrations. Breakthrough DNAemia can occur; surveillance interval and action threshold depend on assay, center, donor/platform, immune therapy and clinical syndrome.

3. CMV DNAemia and Disease Treatment

A reproducible CMV viral-load rise is interpreted against assay, specimen, trend, serostatus, prophylaxis, immune risk and symptoms. Programs set their own preemptive threshold; one value such as 1,000 IU/mL is not universal. Suspected tissue-invasive disease may require organ-directed examination and biopsy while treatment begins when clinically necessary.

Choice and duration depend on marrow reserve, renal function, organ disease, prior exposure/resistance, route and interactions. Trend clinical and virologic response rather than treating until one memorized day.

4. Matching the Monitoring Plan to the CMV Agent

Every agent used against CMV carries a distinct toxicity signature, and the nursing monitoring plan is determined by which drug the patient is receiving rather than by the diagnosis.

• Ganciclovir and valganciclovir are myelosuppressive. Follow the complete blood count closely, because falling neutrophils in a patient still establishing engraftment may force a change in agent rather than a change in dose.
• Foscarnet is nephrotoxic and profoundly disturbs electrolytes, causing hypocalcemia, hypomagnesemia, hypokalemia, and phosphate abnormalities. Pre- and post-infusion hydration is part of the order, not an optional nursing addition, and symptomatic hypocalcemia can present as perioral tingling, cramping, tetany, or seizure.
• Cidofovir is markedly nephrotoxic and is administered with saline hydration and probenecid under a specific protocol; a missed probenecid dose is a reportable deviation rather than a minor omission.
• Letermovir, used for prevention, is comparatively well tolerated but interacts with calcineurin inhibitors, so tacrolimus or cyclosporine levels are monitored when it is started or stopped.
• Maribavir, for refractory or resistant disease, has its own interaction profile and characteristic taste disturbance, which patients tolerate better when warned in advance.

The generalizable point is that "the patient is on CMV treatment" is not an adequate handoff. Name the agent, because the laboratory to watch changes with it.